Effects of GLP-1 Agonists on Gastric Volume

Sponsor
Medical University of South Carolina (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05854979
Collaborator
(none)
210
1
12
17.5

Study Details

Study Description

Brief Summary

This study will enroll patients ages 18 and over who have a diagnosis of diabetes, are undergoing an elective surgery under general anesthesia and 1) are taking a GLP-1 receptor agonist medication, or 2) not taking a GLP-1 receptor agonist medication. The patients will have a gastric ultrasound prior to surgery to measure any retained gastric contents. The primary goal is to assess the effect of subcutaneous injectable GLP-1 agonists on preoperative gastric volume in fasted, diabetic surgical patients.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Gastric Ultrasound

Study Design

Study Type:
Observational
Anticipated Enrollment :
210 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Ultrasound Assessment of Preoperative Gastric Volume in Fasted, Diabetic Surgical Patients: A Prospective Observational Cohort Study on the Effects of GLP-1 Agonists on Gastric Emptying
Anticipated Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Jul 1, 2024
Anticipated Study Completion Date :
Jul 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Diabetics taking a GLP-1 receptor agonist

Diagnostic Test: Gastric Ultrasound
A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.

Diabetics not taking a GLP-1 receptor agonist (control)

Diagnostic Test: Gastric Ultrasound
A gastric ultrasound will be completed on every patient and administered the same way in each arm. The patient will be placed in supine position. A curvilinear ultrasound probe will be placed on the sagittal plane below the xiphoid process. The probe will then slide along the costal margin to the right until the gastric antrum is identified. At this point, the ultrasound image will be obtained, and appropriate measurements will be taken. The patient will be placed in the right lateral decubitus position and the above procedure will be repeated.

Outcome Measures

Primary Outcome Measures

  1. Gastric Volume in RLD Position [From time of enrollment until the start of surgery, assessed up to 4 weeks]

    The gastric volume will be calculated using a validated formula.

Secondary Outcome Measures

  1. Gastric antrum CSA in RLD position [From time of enrollment until the start of surgery, assessed up to 4 weeks]

  2. Perlas antral grade [From time of enrollment until the start of surgery, assessed up to 4 weeks]

  3. Incidence of aspiration [From the time surgery begins until the end of scheduled surgery, assessed up to 24 hours]

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No

Inclusion Criteria

  • Age greater than or equal to 18 years old

  • Diagnosed with diabetes (listed on medical record, Hgb A1C greater than or equal to 6.5%, fasting blood glucose greater than or equal to 126mg/dL, and/or on medical treatment for diabetes)

  • One of the following groups:

  • Taking a GLP-1 Medication

  • Not taking a GLP-1 Medication

  • ASA Physical Classification Status 1-3

  • Scheduled for elective surgery under general anesthesia

  • Appropriately fasted per ASA Fasting Guidelines 201712

Exclusion Criteria

  • BMI greater than 40

  • Previous gastric/esophageal surgery

  • Abnormal gastric anatomy

  • Pregnancy

  • Inability or unwillingness of subject to give informed consent

  • Non-English Speaking

Contacts and Locations

Locations

Site City State Country Postal Code
1 Medical University of South Carolina Charleston South Carolina United States 29425

Sponsors and Collaborators

  • Medical University of South Carolina

Investigators

  • Principal Investigator: Christopher Wolla, M.D., Medical University of South Carolina

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Christopher Wolla, Principal Investigator, Assistant Professor, Medical University of South Carolina
ClinicalTrials.gov Identifier:
NCT05854979
Other Study ID Numbers:
  • Pro00128783
First Posted:
May 11, 2023
Last Update Posted:
May 11, 2023
Last Verified:
May 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 11, 2023